MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Sells $1,960,400.00 in Stock

MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos sold 130,000 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $15.08, for a total value of $1,960,400.00. Following the completion of the sale, the chief executive officer directly owned 2,948,577 shares of the company’s stock, valued at $44,464,541.16. The trade was a 4.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Da Silva Jorge Santos also recently made the following trade(s):

• On Tuesday, December 9th, Da Silva Jorge Santos sold 70,000 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $14.49, for a total value of $1,014,300.00.

MoonLake Immunotherapeutics Price Performance

Shares of MLTX stock opened at $14.79 on Friday. MoonLake Immunotherapeutics has a fifty-two week low of $5.95 and a fifty-two week high of $62.75. The company has a debt-to-equity ratio of 0.25, a quick ratio of 8.50 and a current ratio of 8.50. The firm has a market capitalization of $949.96 million, a price-to-earnings ratio of -4.45 and a beta of 1.21. The stock’s 50-day simple moving average is $11.62 and its 200-day simple moving average is $35.78.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Wednesday, November 5th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.21). During the same period in the prior year, the business posted ($0.56) EPS. As a group, equities analysts forecast that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC raised its position in shares of MoonLake Immunotherapeutics by 0.9% during the 2nd quarter. Geode Capital Management LLC now owns 59,553 shares of the company’s stock worth $2,809,000 after purchasing an additional 559 shares during the last quarter. Squarepoint Ops LLC increased its stake in MoonLake Immunotherapeutics by 3.7% during the 2nd quarter. Squarepoint Ops LLC now owns 17,571 shares of the company’s stock worth $829,000 after buying an additional 629 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of MoonLake Immunotherapeutics by 8.2% during the first quarter. PNC Financial Services Group Inc. now owns 9,200 shares of the company’s stock valued at $359,000 after acquiring an additional 700 shares during the last quarter. MPM Bioimpact LLC lifted its position in shares of MoonLake Immunotherapeutics by 0.3% in the first quarter. MPM Bioimpact LLC now owns 316,049 shares of the company’s stock valued at $12,348,000 after acquiring an additional 819 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in shares of MoonLake Immunotherapeutics by 18.9% in the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock worth $52,000 after acquiring an additional 1,158 shares during the last quarter. Hedge funds and other institutional investors own 93.85% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. The Goldman Sachs Group restated a “neutral” rating and issued a $7.00 target price on shares of MoonLake Immunotherapeutics in a research note on Wednesday, October 1st. Stifel Nicolaus cut MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $13.00 price objective for the company. in a research note on Monday, September 29th. Oppenheimer reiterated an “outperform” rating and issued a $30.00 target price on shares of MoonLake Immunotherapeutics in a research report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of MoonLake Immunotherapeutics in a research report on Wednesday, October 8th. Finally, Guggenheim decreased their price objective on shares of MoonLake Immunotherapeutics from $80.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 30th. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics has a consensus rating of “Hold” and an average target price of $30.25.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.